echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > Dongyangguang pharmaceutical is expected to make an annual turnover of 6.22 billion and join hands with China Resources pharmaceutical to enter online channels

    Dongyangguang pharmaceutical is expected to make an annual turnover of 6.22 billion and join hands with China Resources pharmaceutical to enter online channels

    • Last Update: 2020-01-05
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    On January 2, dongyangyao announced that, based on the current available unaudited comprehensive management accounts and the preliminary estimates of the company's management, the Group expects the company's turnover to be about 6.22 billion yuan as of December 31, 2019, an increase of about 145% over that of 2018; from October 1, 2019 to December 31, 2019, namely, the three months of Q4, the turnover is obtained by RMB 1.78 billion, an increase of 125% over the same period of 2018 According to the announcement, the expected growth of the company's turnover is mainly due to the continuous growth of the sales volume of core products, the continuous expansion of the product portfolio, the continuous improvement of the penetration rate of products in the national medical institutions and the continuous enhancement of the company's product promotion in the professional academic market In addition, on January 3, dongyangyao announced that it has entered into a strategic cooperation framework agreement with China Resources Pharmaceutical Business Group Co., Ltd., which will jointly develop Internet channels with the help of the distribution network and drug storage capacity of China Resources pharmaceutical business, devote itself to the construction of direct service terminals and online channels for patients, and enhance the core product "Kewei" ”Response of oseltamivir phosphate series to sudden national demand, and strengthen terminal coverage of other products The cooperation period of the strategic cooperation framework agreement is three years.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.